View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant F...

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 31, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Relay Therapeutics to Participate in Two Upcoming Investor Conferences...

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats in June: Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:45 a.m. ETGoldman Sachs Global Healthcare Conference on Wednesday, June 11, 2025 at 2:40 p.m. ET The fireside chats will be webcast...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: May 28, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydroc...

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution • KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million DEER PARK, Ill., May 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Foo...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 24, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

The Tile Shop to Debut Exclusive Tile Collection With Nate Berkus

The Tile Shop to Debut Exclusive Tile Collection With Nate Berkus The Tile Shop x Nate Berkus will arrive at all U.S. Tile Shop showrooms and tileshop.com starting fall 2026. MINNEAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- The Tile Shop  () today announced a new collaboration with award-winning designer Nate Berkus. The Tile Shop x Nate Berkus, available exclusively at The Tile Shop, will debut in Tile Shop showrooms and on tileshop.com in early fall 2026. The Tile Shop x Nate Berkus collection will feature floor and wall tiles, in a diverse range of materials and shapes, anchored in a pa...

 PRESS RELEASE

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, and David Krempa, Chief Business Officer, will participate in two upcoming investor conferences as follows: The 25th Annual B. Riley Securities Investor ConferenceDate: Thursday, May 22, 2025, at ...

 PRESS RELEASE

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully diluted EPS of $0.07, and Adjusted EBITDA of $3.7 millionRelaunched pediatric endocrinology biologic INCRELEX® in the U.S. and out-licensed international rightsEstablished Wilson disease franchise with the acquisition and relaunch of GALZIN® (zinc acetate) capsules and the introduction of p...

 PRESS RELEASE

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: BoA Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 3:40 p.m. PTTD Cowen’s 6th Annual Oncology Innovation Summit on Tuesday, May 27, 2025 at 3:30 p.m. ET The fireside chats will be webcast live and ...

 PRESS RELEASE

The Tile Shop Reports First Quarter 2025 Results

The Tile Shop Reports First Quarter 2025 Results MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles today announced results for its first quarter ended March 31, 2025.   First Quarter 2025 Summary Net Sales Decreased 4.1%Comparable Store Sales Decreased 4.0% Gross Margin of 66.0%Net Income of $0.2 Million and Adjusted EBITDA of $4.6 MillionNo Debt Outstanding and $27.1 million of Cash at Quarter-End Management Commentary – Cabell Lolmaugh, CEO “While hou...

 PRESS RELEASE

Relay Therapeutics Reports First Quarter 2025 Financial Results and Co...

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a cl...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch